Ce bout la me semble étrange:
Or quel est l'intérêt d'un vaccin généralisé pour une maladie dont la mortalité est proche de 0,05% ?
L'Italie a 60,000 mort, 0.05% de 60 millions d'italien est environ 30,000 personnes, 0.05% d'américain c'est 165,000 ils ont plus de 300,000 morts, ça fait peut de sens.
Bien des pays ont significativement plus de 0.05% de leur population totale mort du virus, je doute que ça mortalité est proche de 0.05%, voulait-il dire 0.5% et a fait un typo ? Mais bref s'il se mélange d'un facteur 10 sur la mortalité d'un virus son point de vue sur le risque qui en vaut la peine est complètement déplacer évidemment.
Il dit aussi que L'efficacité de l'hydrocloxine avec azithromycine est largement prouvé ??
https://www.nejm.org/doi/full/10.1056/NEJMoa2016638We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The
incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was ?2.4 percentage points (95% confidence interval, ?7.0 to 2.2; P=0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported.
https://www.nejm.org/doi/full/10.1056/NEJMoa2022926?query=featured_homeThe enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy.
Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P=0.15). Consistent results were seen in all prespecified subgroups of patients. The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98). Among the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine.
https://www.nejm.org/doi/full/10.1056/nejmoa2019014A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care,
the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P=1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P=1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent.
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30505-X/fulltextAfter excluding studies with critical risk of bias, the meta-analysis included 11 932 participants for the hydroxychloroquine group, 8081 for the hydroxychloroquine with azithromycin group and 12 930 for the control group. Hydroxychloroquine was not significantly associated with mortality: pooled relative risk (RR) 0.83 (95% CI 0.65–1.06, n = 17 studies) for all studies and RR = 1.09 (95% CI 0.97–1.24, n = 3 studies) for randomized controlled trials. Hydroxychloroquine with azithromycin was associated with an increased mortality (RR = 1.27; 95% CI 1.04–1.54, n = 7 studies). We found similar results with a Bayesian meta-analysis.
Among patients hospitalized with Covid-19,
those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care.
Hydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients
but the combination of hydroxychloroquine and azithromycin significantly increased mortality.
Sondage